Syros Pharmaceuticals (SYRS) Misses Q4 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Syros Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Multiple Upcoming Clinical Milestones for Its First-in-Class Programs
March 7, 2019 7:30 AM ESTExpects to Report Updated Data on SY-1425 in Combination with Azacitidine in Newly Diagnosed Unfit AML Patients in Second Half of 2019
Expects to Report Initial Data from Expansion Portion of Phase 1 Trial of SY-1365 in Fourth Quarter of 2019
Announces Plans to Expand Ongoing Phase 2 Trial of SY-1425 in Combination with Azacitidine to Include Biomarker-Positive Relapsed or Refractory AML Patients
Announces New Expansion Cohort to Evaluate SY-1365 in Recurrent Ovarian Clear Cell Cancer Patients
Management to Host Conference Call at 8:30 a.m. ET... More
